These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25367933)

  • 1. PD-1 inhibitor approved for melanoma.
    Cancer Discov; 2014 Nov; 4(11):1249. PubMed ID: 25367933
    [No Abstract]   [Full Text] [Related]  

  • 2. Programmed death protein 1 inhibitors making inroads in multiple cancers.
    Brower V
    J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25957444
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunotherapy for melanoma using programmed death 1 checkpoint inhibitors.
    Hamid O
    Clin Adv Hematol Oncol; 2014 Nov; 12(11):782-4. PubMed ID: 25674719
    [No Abstract]   [Full Text] [Related]  

  • 4. PD-1 Blockers.
    Wolchok JD
    Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma.
    Hersey P; Gowrishankar K
    Future Oncol; 2015; 11(1):133-40. PubMed ID: 25572788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab: first global approval.
    Poole RM
    Drugs; 2014 Oct; 74(16):1973-1981. PubMed ID: 25331768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.
    Longoria TC; Tewari KS
    Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1247-53. PubMed ID: 27485741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab for the treatment of melanoma.
    Kumar SS; McNeil CM
    Expert Rev Clin Pharmacol; 2015; 8(5):515-27. PubMed ID: 26146011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous Metastatic Melanoma Resembling a Halo Nevus, in the Setting of PD-1 Inhibition.
    Harvey NT; Millward M; Macgregor K; Bucat RP; Wood BA
    Am J Dermatopathol; 2016 Dec; 38(12):e159-e162. PubMed ID: 27870733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands.
    van der Kooij MK; Joosse A; Speetjens FM; Hospers GA; Bisschop C; de Groot JW; Koornstra R; Blank CU; Kapiteijn E
    Acta Oncol; 2017 Jan; 56(1):101-103. PubMed ID: 27911126
    [No Abstract]   [Full Text] [Related]  

  • 11. PD-1 inhibitors effective in hodgkin lymphoma.
    Cancer Discov; 2015 Feb; 5(2):102-3. PubMed ID: 25656882
    [No Abstract]   [Full Text] [Related]  

  • 12. Resistance to PD-1 blockade in melanoma.
    Burki TK
    Lancet Oncol; 2016 Sep; 17(9):e376. PubMed ID: 27452143
    [No Abstract]   [Full Text] [Related]  

  • 13. Focal regression of a primary melanoma, fading lentigines and poliosis in metastatic melanoma treated with anti-PD-1.
    Thomas S; Laino A; Sturm R; Nufer K; Lambie D; Shepherd B; Atkinson V; Adams L; Soyer HP; Schaider H
    J Eur Acad Dermatol Venereol; 2018 May; 32(5):e176-e177. PubMed ID: 29114959
    [No Abstract]   [Full Text] [Related]  

  • 14. American Association of Cancer Research Showcases Immunotherapy Advances.
    Brower V
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26243202
    [No Abstract]   [Full Text] [Related]  

  • 15. Toripalimab: First Global Approval.
    Keam SJ
    Drugs; 2019 Apr; 79(5):573-578. PubMed ID: 30805896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scleroderma Induced by Pembrolizumab: A Case Series.
    Barbosa NS; Wetter DA; Wieland CN; Shenoy NK; Markovic SN; Thanarajasingam U
    Mayo Clin Proc; 2017 Jul; 92(7):1158-1163. PubMed ID: 28599746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of metastatic mucosal melanoma with a Del579 c-KIT mutation by imatinib after treatment of anti-PD-1 antibody.
    Yamashita C; Otsuka A; Nomura M; Honda T; Kabashima K
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):e92-e93. PubMed ID: 30199578
    [No Abstract]   [Full Text] [Related]  

  • 18. Squamous cell carcinoma associated with chronic graft versus host disease-like/lichen planus-like lesion of the oral cavity in a patient managed for metastatic melanoma with a PD-1 inhibitor pembrolizumab.
    Owosho AA; Randazzo J; Rosen EB; Estilo CL; Huryn JM; Chi P; Yom SK
    Oral Oncol; 2016 Dec; 63():e1-e3. PubMed ID: 27743938
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease.
    Maul LV; Weichenthal M; Kähler KC; Hauschild A
    J Immunother; 2016 May; 39(4):188-90. PubMed ID: 27023060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.
    Hugo W; Zaretsky JM; Sun L; Song C; Moreno BH; Hu-Lieskovan S; Berent-Maoz B; Pang J; Chmielowski B; Cherry G; Seja E; Lomeli S; Kong X; Kelley MC; Sosman JA; Johnson DB; Ribas A; Lo RS
    Cell; 2016 Mar; 165(1):35-44. PubMed ID: 26997480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.